Last reviewed · How we verify
Premature Luteinizing Hormone Surges — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cetrotide | CETRORELIX | Merck KGaA | Gonadotropin Releasing Hormone Receptor Antagonist | Gonadotropin-releasing hormone receptor | 2000-01-01 | |
| Cetrotide | Cetrotide | Wolfson Medical Center | Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Cetrotide · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Merck KGaA · 1 drug in Premature Luteinizing Hormone Surges
- Wolfson Medical Center · 1 drug in Premature Luteinizing Hormone Surges
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Premature Luteinizing Hormone Surges:
- Premature Luteinizing Hormone Surges treatment updates — RSS
- Premature Luteinizing Hormone Surges treatment updates — Atom
- Premature Luteinizing Hormone Surges treatment updates — JSON
Cite this brief
Drug Landscape (2026). Premature Luteinizing Hormone Surges — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/premature-luteinizing-hormone-surges. Accessed 2026-06-11.
Related
- Premature Luteinizing Hormone Surges full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing